Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
853 Stock Overview
MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People’s Republic of China, North America, Europe, other Asian countries, South America, and internationally.
MicroPort Scientific Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$23.15 |
52 Week High | HK$72.85 |
52 Week Low | HK$12.24 |
Beta | 0.069 |
1 Month Change | 68.98% |
3 Month Change | 31.39% |
1 Year Change | -67.23% |
3 Year Change | 299.14% |
5 Year Change | 276.42% |
Change since IPO | 179.25% |
Recent News & Updates
Is MicroPort Scientific (HKG:853) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Shareholder Returns
853 | HK Medical Equipment | HK Market | |
---|---|---|---|
7D | 27.1% | 15.3% | 2.1% |
1Y | -67.2% | -60.3% | -23.3% |
Return vs Industry: 853 underperformed the Hong Kong Medical Equipment industry which returned -60.3% over the past year.
Return vs Market: 853 underperformed the Hong Kong Market which returned -23.3% over the past year.
Price Volatility
853 volatility | |
---|---|
853 Average Weekly Movement | 11.2% |
Medical Equipment Industry Average Movement | 9.1% |
Market Average Movement | 7.0% |
10% most volatile stocks in HK Market | 13.8% |
10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 853 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 853's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 8,019 | Maxwell Chang | https://www.microport.com |
MicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People’s Republic of China, North America, Europe, other Asian countries, South America, and internationally. The company’s Cardiovascular Devices segment offers products and services for the treatment of coronary artery-related diseases; coronary stents and related delivery systems; and balloon catheters and accessories. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma, and other professional implants and instruments.
MicroPort Scientific Fundamentals Summary
853 fundamental statistics | |
---|---|
Market Cap | US$5.36b |
Earnings (TTM) | -US$276.48m |
Revenue (TTM) | US$778.64m |
6.9x
P/S Ratio-19.4x
P/E RatioIs 853 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
853 income statement (TTM) | |
---|---|
Revenue | US$778.64m |
Cost of Revenue | US$286.87m |
Gross Profit | US$491.77m |
Other Expenses | US$768.26m |
Earnings | -US$276.48m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | -0.15 |
Gross Margin | 63.16% |
Net Profit Margin | -35.51% |
Debt/Equity Ratio | 46.2% |
How did 853 perform over the long term?
See historical performance and comparisonValuation
Is 853 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 853?
Other financial metrics that can be useful for relative valuation.
What is 853's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$5.36b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 7.1x |
Enterprise Value/EBITDA | -21.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 853's PS Ratio compare to its peers?
853 PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3414.8x |
Price-To-Sales vs Peers: 853 is good value based on its Price-To-Sales Ratio (6.9x) compared to the peer average (3414.8x).
Price to Earnings Ratio vs Industry
How does 853's PE Ratio compare vs other companies in the Hong Kong Medical Equipment Industry?
Price-To-Sales vs Industry: 853 is expensive based on its Price-To-Sales Ratio (6.9x) compared to the Hong Kong Medical Equipment industry average (6.2x)
Price to Sales Ratio vs Fair Ratio
What is 853's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 6.9x |
Fair PS Ratio | 7.6x |
Price-To-Sales vs Fair Ratio: 853 is good value based on its Price-To-Sales Ratio (6.9x) compared to the estimated Fair Price-To-Sales Ratio (7.6x).
Share Price vs Fair Value
What is the Fair Price of 853 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 853's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 853's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 853's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is MicroPort Scientific forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
18.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 853 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 853 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 853 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 853's revenue (19.4% per year) is forecast to grow faster than the Hong Kong market (10.3% per year).
High Growth Revenue: 853's revenue (19.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 853 is forecast to be unprofitable in 3 years.
Discover growth companies
Past Performance
How has MicroPort Scientific performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-69.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 853 is currently unprofitable.
Growing Profit Margin: 853 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 853 is unprofitable, and losses have increased over the past 5 years at a rate of 69.9% per year.
Accelerating Growth: Unable to compare 853's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 853 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (35.4%).
Return on Equity
High ROE: 853 has a negative Return on Equity (-15.84%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is MicroPort Scientific's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 853's short term assets ($2.4B) exceed its short term liabilities ($546.8M).
Long Term Liabilities: 853's short term assets ($2.4B) exceed its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: 853 has more cash than its total debt.
Reducing Debt: 853's debt to equity ratio has reduced from 83.1% to 46.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 853 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 853 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Dividend
What is MicroPort Scientific current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 853's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 853's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 853's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 853's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: 853 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 853 has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
9.7yrs
Average management tenure
CEO
Maxwell Chang (58 yo)
24.42yrs
Tenure
US$49,135,000
Compensation
Dr. Zhaohua Chang,Ph D also known as Maxwell, serves as the Chief Executive Officer Shanghai MicroPort Medical (Group) Co., Ltd. He serves as the Chairman of MicroPort Scientific Corporation and serves as...
CEO Compensation Analysis
Compensation vs Market: Maxwell's total compensation ($USD49.14M) is above average for companies of similar size in the Hong Kong market ($USD626.60K).
Compensation vs Earnings: Maxwell's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: 853's management team is seasoned and experienced (9.7 years average tenure).
Board Members
Experienced Board: 853's board of directors are seasoned and experienced ( 11.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
MicroPort Scientific Corporation's employee growth, exchange listings and data sources
Key Information
- Name: MicroPort Scientific Corporation
- Ticker: 853
- Exchange: SEHK
- Founded: 1998
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: HK$42.046b
- Shares outstanding: 1.82b
- Website: https://www.microport.com
Number of Employees
Location
- MicroPort Scientific Corporation
- 1601 Zhangdong Road
- Zhangjiang Hi-Tech Park
- Shanghai
- 201203
- China
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/26 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.